Ideaya Biosciences Inc (IDYA)

NASD · Healthcare · Biotechnology · USA

Ideaya Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Ideaya Biosciences is a precision medicine oncology company developing targeted therapies for cancer by combining small-molecule drug discovery with biomarker validation. Its pipeline spans four therapeutic areas including darovasertib for uveal melanoma, antibody-drug conjugate combinations, MTAP pathway programs, and next generation treatments, supported through collaborations with pharmaceutical partners.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Ideaya Biosciences Inc stock.

Our verdict on IDYA

Overvalued: intrinsic value $6.00 per share, market price $27.40, margin of safety -356.5% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $6.00; the price of $27.40 is 357% above that value.

ETFs with the most weight in IDYA

17 more funds hold it; the full list is part of the paid plan.

More on IDYA

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than IDYA in Biotechnology

79 more in this industry show a wider margin of safety.

Is IDYA undervalued or overvalued?

IDYA is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.00; the price of $27.40 is 357% above that value.

What is the intrinsic value of IDYA?

$6.00 per share (as of the 2026-11-17 close), against a market price of $27.40. That is a margin of safety of -356.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.